Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer

Core Insights - Aligos Therapeutics has appointed James Hassard as Executive Vice President and Chief Commercial Officer to enhance its global commercial capabilities [1][2] - The company is advancing the Phase 2 B-SUPREME study of pevifoscorvir sodium and is preparing for its commercial launch [2] - Aligos focuses on developing therapies for liver and viral diseases, with a strong emphasis on chronic hepatitis B virus infection and other high unmet medical needs [3] Company Overview - Aligos Therapeutics, Inc. is a clinical stage biotechnology company dedicated to improving patient outcomes through innovative therapies for liver and viral diseases [3] - The company utilizes a science-driven approach and has a purpose-built pipeline targeting conditions such as chronic hepatitis B virus infection, obesity, metabolic dysfunction-associated steatohepatitis, and coronaviruses [3] Leadership Background - James Hassard brings extensive experience in building commercial organizations across various therapeutic areas, having previously served as Chief Commercial Officer at Crinetics Pharmaceuticals and Arrowhead Pharmaceuticals [2] - His career includes significant roles at Coherus Oncology, Amgen, and Merck, where he launched multiple pharmaceutical products in areas including hepatitis, oncology, and nephrology [2] - Hassard holds a Bachelor of Science in Pharmacology and an MBA, indicating a strong educational background relevant to his new role [2]